US FDA issues four observations for Biocon’s Bengaluru API facility

Biocon has not disclosed the specifics of the observations, but in an exchange filing, the company said that it would address the cited observations within the stipulated time. “The Company does not foresee any impact on the business,” Biocon said.

Leave a Reply

Your email address will not be published. Required fields are marked *